Health and Fitness Health and Fitness
Thu, June 18, 2009
Wed, June 17, 2009
Tue, June 16, 2009
Mon, June 15, 2009
Fri, June 12, 2009
Thu, June 11, 2009
Wed, June 10, 2009
Tue, June 9, 2009
Mon, June 8, 2009
Sun, June 7, 2009
Fri, June 5, 2009
Thu, June 4, 2009
Wed, June 3, 2009
Tue, June 2, 2009
Mon, June 1, 2009
Sat, May 30, 2009
Fri, May 29, 2009
Thu, May 28, 2009
Wed, May 27, 2009
Tue, May 26, 2009
Mon, May 25, 2009
Fri, May 22, 2009
Thu, May 21, 2009
Wed, May 20, 2009
Tue, May 19, 2009
Mon, May 18, 2009
Fri, May 15, 2009
Thu, May 14, 2009
Wed, May 13, 2009
Tue, May 12, 2009
Mon, May 11, 2009
Fri, May 8, 2009
Thu, May 7, 2009
Thu, April 16, 2009
Wed, April 15, 2009
Tue, April 14, 2009
Mon, April 13, 2009
Fri, April 10, 2009
Thu, April 9, 2009
Wed, April 8, 2009
Tue, April 7, 2009
Mon, April 6, 2009
Fri, April 3, 2009
Thu, April 2, 2009
Wed, April 1, 2009
Tue, March 31, 2009
Mon, March 30, 2009
Fri, March 27, 2009
Thu, March 26, 2009
Wed, March 25, 2009
Tue, March 24, 2009
Mon, March 23, 2009
Fri, March 20, 2009
Thu, March 19, 2009
Wed, March 18, 2009
Tue, March 17, 2009

Skyepharma PLC: Skyepharma PLC announces Board Appointment


//health-fitness.news-articles.net/content/2009/ .. -skyepharma-plc-announces-board-appointment.html
Published in Health and Fitness on Thursday, May 14th 2009 at 23:34 GMT, Last Modified on 2009-11-02 12:09:57 by Market Wire   Print publication without navigation


London, UK--(Marketwire - May 15, 2009) -

 Appointment of New Non-Executive Director LONDON, UK, 15 May, 2009 - SkyePharma PLC (LSE: SKP) today announces that it will appoint a new Non-Executive Director, Dr Thomas Werner, to the Board with effect from 16 May 2009. Dr Werner, 52, is a senior-level pharmaceutical executive with over 26 years experience in the pharmaceutical industry, most recently as Managing Director and Senior Vice-President of GlaxoSmithKline Germany. Prior to that, he held senior positions at GlaxoWellcome Germany, Bristol-Myers Squibb Germany and Convatec Germany, (a medical devices subsidiary of Bristol Myers Squibb). Dr Werner sits on the Board of Trustees of both the Paul Ehrlich Association and the Robert Koch Foundation. No disclosures are required under section 9.6.13 of the Listing Rules. As previously announced Dr Argeris (Jerry) Karabelas will stand down from the Board at the conclusion of the Annual General Meeting taking place later today. Jeremy Scudamore, Non-Executive Chairman of SkyePharma, said: "On behalf of the Board and staff, I would like to reiterate my thanks to Jerry for the tremendous contribution he has made to the Company over the past eight years and to welcome Thomas to the Board of SkyePharma. His experience as a senior international manager in the pharmaceutical industry will enable him to be of significant value to SkyePharma as it moves forward." For further information please contact: SkyePharma PLC Ken Cunningham +44 20 7491 1777 Peter Grant Financial Dynamics Jonathan Birt +44 20 7831 3113 Susan Quigley About SkyePharma PLC Using its proprietary drug delivery technologies, SkyePharma develops new formulations of existing products to provide a clinical advantage and life-cycle extension. The Group has twelve approved products in the areas of oral, inhalation and topical delivery. The Group's products are marketed throughout the world by leading pharmaceutical companies. For more information, visit [ www.skyepharma.com ]. This information is provided by RNS The company news service from the London Stock Exchange END 


Publication Contributing Sources